Literature DB >> 14970

Insulin, proinsulin, glucagon and gastrin in pancreatic tumors and in plasma of patients with organic hyperinsulinism.

M Hayashi, J C Floyd, S Pek, S S Fajans.   

Abstract

Insulin, proinsulin, glucagon and gastrin were determined in extracts of tumors of 27 patients with pancreatic islet cell neoplasia of pancreas, in one patient with nesidioblastosis, in extracts of uninvolved portions of the pancreas in 11 of the tumor patients and of 15 control pancreases. Mean insulin concentration in solitary adenomas and in adenomas of patients with adenomatosis was higher than in control pancreases; however, in all but 1 patient the insulin concentration in neoplastic islet tissue was lower than in islet tissue of control pancreas, assuming islet volume is 1% of pancreas. The percentage of proinsulin was elevated in 52% of tumors. Adenoma insulin content correlated with increments of plasma insulin after tolbutamide administration. Insulin and proinsulin concentrations in pancreas uninvolved by tumor were not suppressed. Fasting plasma glucagon was elevated in patients with islet cell adenomatosis and in patients with islet cell carcinoma some of whom had multiple endocrine adenomatosis. The mean concentration of glucagon in tumors was lower than in control pancreases. Elevated concentration of gastrin was found in some adenomas. The data indicate: 1) insulin-secreting islet cell tumors have decreased storage capacity for insulin, 2) elevated concentration of proinsulin in tumors may be due to decreased capacity to store insulin and in some to decreased conversion of proinsulin to insulin as well, 3) tolbutamide stimulates the exaggerated release of a relatively constant fraction of insulin stored in adenomas. 4) solitary adenomas may contain excess amounts of pancreatic hormones in addition to insulin, 5) elevated plasma glucagon in patients with organic hyperinsulinism may indicate malignancy, microadenomatosis or multiple endocrine adenoma syndrome, and 6) chronic hyperinsulinism and hypoglycemia due to adenoma do not suppress insulin and proinsulin content of uninvolved pancreas.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 14970     DOI: 10.1210/jcem-44-4-681

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  14 in total

Review 1.  Diagnosis of Zollinger-Ellison syndrome: increasingly difficult.

Authors:  Tetsuhide Ito; Guillaume Cadiot; Robert T Jensen
Journal:  World J Gastroenterol       Date:  2012-10-21       Impact factor: 5.742

2.  The value of artificial beta cell in the management of insulinoma.

Authors:  L J Valenta; H Eisenberg; D R Miller; S M Tanner; S G Romansky; A H Rubenstein; M Mako; B F Cullen; M P Golden; A N Elias
Journal:  West J Med       Date:  1982-07

3.  Diagnosis of Zollinger-Ellison syndrome in the era of PPIs, faulty gastrin assays, sensitive imaging and limited access to acid secretory testing.

Authors:  David C Metz; Guillaume Cadiot; Pierre Poitras; Tetsuhide Ito; Robert T Jensen
Journal:  Int J Endocr Oncol       Date:  2017-10-11

4.  Reduction of insulin resistance with effective clearance of hepatitis C infection: results from the HALT-C trial.

Authors:  Aymin Delgado-Borrego; Sergio H Jordan; Betania Negre; David Healey; Wenyu Lin; Yoshitaka Kamegaya; Marielle Christofi; David A Ludwig; Anna S F Lok; Raymond T Chung
Journal:  Clin Gastroenterol Hepatol       Date:  2010-02-12       Impact factor: 11.382

5.  Weight-related effects on disease progression in the hepatitis C antiviral long-term treatment against cirrhosis trial.

Authors:  James E Everhart; Anna S Lok; Hae-Young Kim; Timothy R Morgan; Karen L Lindsay; Raymond T Chung; Herbert L Bonkovsky; Marc G Ghany
Journal:  Gastroenterology       Date:  2009-05-13       Impact factor: 22.682

6.  Adipose tissue glycogen synthase activation by in vivo insulin in spontaneously insulin-resistant and type 2 (non-insulin-dependent) diabetic rhesus monkeys.

Authors:  H K Ortmeyer; N L Bodkin; B C Hansen
Journal:  Diabetologia       Date:  1993-03       Impact factor: 10.122

7.  Heterogeneity of insulin responses: phases leading to type 2 (non-insulin-dependent) diabetes mellitus in the rhesus monkey.

Authors:  B C Hansen; N L Bodkin
Journal:  Diabetologia       Date:  1986-10       Impact factor: 10.122

8.  Hyperuricemia in glycogen storage disease type I. Contributions by hypoglycemia and hyperglucagonemia to increased urate production.

Authors:  J L Cohen; A Vinik; J Faller; I H Fox
Journal:  J Clin Invest       Date:  1985-01       Impact factor: 14.808

9.  Gut-hormone profile in totally pancreatectomised patients.

Authors:  H G Dammann; H S Besterman; S R Bloom; H W Schreiber
Journal:  Gut       Date:  1981-02       Impact factor: 23.059

10.  The effect of treatment of type 2 (insulin independent) diabetes mellitus on plasma concentrations of pancreatic polypeptide and glucagon.

Authors:  D Berger; J C Floyd; S B Pek
Journal:  Diabetologia       Date:  1981-08       Impact factor: 10.122

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.